Literature DB >> 17954694

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

J A Passarell1, A K Meagher, K Liolios, B B Cirincione, S A Van Wart, T Babinchak, E J Ellis-Grosse, P G Ambrose.   

Abstract

Exposure-response analyses were performed to test the microbiological and clinical efficacies of tigecycline in complicated intra-abdominal infections where Escherichia coli and Bacteroides fragilis are the predominant pathogens. Data from evaluable patients enrolled in three clinical trials were pooled. Patients received intravenous tigecycline (100-mg loading dose followed by 50 mg every 12 h or 50-mg loading dose followed by 25 mg every 12 h). At the test-of-cure visit, microbiological and clinical responses were evaluated. Patients were prospectively classified into cohorts based on infection with a baseline pathogen(s): E. coli only (cohort 1), other mono- or polymicrobial Enterobacteriaceae (cohort 2), at least one Enterobacteriaceae pathogen plus an anaerobe(s) (cohort 3), at least one Enterobacteriaceae pathogen plus a gram-positive pathogen(s) (cohort 4), and all other pathogens (cohort 5). The cohorts were prospectively combined to increase sample size. Logistic regression was used to evaluate ratio of steady-state 24-hour area under the concentration-time curve (AUC) to MIC as a response predictor, and classification-and-regression-tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with cohorts 1, 2, and 3 pooled, which included 71 patients, with 106 pathogens. The small sample size precluded evaluation of cohorts 1 (34 patients, 35 E. coli pathogens) and 2 (16 patients, 24 Enterobacteriaceae). CART analyses identified a significant AUC/MIC breakpoint of 6.96 for microbiological and clinical responses (P values of 0.0004 and 0.399, respectively). The continuous AUC/MIC ratio was also borderline predictive of microbiological response (P = 0.0568). Cohort 4 (21 patients, 50 pathogens) was evaluated separately; however, an exposure-response relationship was not detected; cohort 5 (31 patients, 60 pathogens) was not evaluated. The prospective approach of creating homogenous populations of pathogens was critical for identifying exposure-response relationships in complicated intra-abdominal infections.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954694      PMCID: PMC2223921          DOI: 10.1128/AAC.00813-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  The bacteriology of intra-abdominal infections.

Authors:  B Lorber; R M Swenson
Journal:  Surg Clin North Am       Date:  1975-12       Impact factor: 2.741

2.  Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome.

Authors:  N V Christou; P S Barie; E P Dellinger; J P Waymack; H H Stone
Journal:  Arch Surg       Date:  1993-02

3.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Authors:  A K Meagher; J A Passarell; B B Cirincione; S A Van Wart; K Liolios; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

5.  Regression modelling strategies for improved prognostic prediction.

Authors:  F E Harrell; K L Lee; R M Califf; D B Pryor; R A Rosati
Journal:  Stat Med       Date:  1984 Apr-Jun       Impact factor: 2.373

Review 6.  A review. Lessons from an animal model of intra-abdominal sepsis.

Authors:  J G Bartlett; A B Onderdonk; T Louie; D L Kasper; S L Gorbach
Journal:  Arch Surg       Date:  1978-07

7.  Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model.

Authors:  A B Onderdonk; R B Markham; D F Zaleznik; R L Cisneros; D L Kasper
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

8.  APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.

Authors:  W A Knaus; J E Zimmerman; D P Wagner; E A Draper; D E Lawrence
Journal:  Crit Care Med       Date:  1981-08       Impact factor: 7.598

Review 9.  Antimicrobial prophylaxis for appendectomy and colorectal surgery.

Authors:  S L Gorbach
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

10.  Surgical infection stratification system for intra-abdominal infection. Multicenter trial.

Authors:  E P Dellinger; M J Wertz; J L Meakins; J S Solomkin; M D Allo; R J Howard; R L Simmons
Journal:  Arch Surg       Date:  1985-01
View more
  26 in total

1.  Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.

Authors:  Christopher M Rubino; Alan Forrest; Sujata M Bhavnani; Gary Dukart; Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Jeffrey P Hammel; Alan Forrest; Nathalie Dartois; C Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics.

Authors:  Paul G Ambrose; Jeffrey P Hammel; Sujata M Bhavnani; Christopher M Rubino; Evelyn J Ellis-Grosse; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Multi-drug-resistant Klebsiella pneumoniae pancreatitis: a new challenge in a serious surgical infection.

Authors:  Derin Tugal; Melanie Lynch; Andrea M Hujer; Susan Rudin; Federico Perez; Robert A Bonomo
Journal:  Surg Infect (Larchmt)       Date:  2014-05-21       Impact factor: 2.150

Review 5.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

6.  Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.

Authors:  Julio Ramirez; Nathalie Dartois; Hassan Gandjini; Jean Li Yan; Joan Korth-Bradley; Paul C McGovern
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.

Authors:  Christopher M Rubino; Sujata M Bhavnani; Alan Forrest; Gary Dukart; Nathalie Dartois; Angel Cooper; Joan Korth-Bradley; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 8.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

9.  In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006.

Authors:  C-Y Liu; C-L Lu; Y-T Huang; C-H Liao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-09-08       Impact factor: 3.267

Review 10.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.